CoChat
Sign Up
Cited by 891Chemokine receptors and signalingImmune Response and InflammationAntimicrobial Peptides and Activities

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Specific Recruitment of Antigen-presenting Cells by Chemerin, a Novel Processed Ligand from Human Inflammatory Fluids

Open access
Wittamer, Valérie, Franssen, Jean-Denis, Vulcano, Marisa, Mirjolet, Jean-François, Le Poul, Emmanuel, Migeotte, Isabelle, Brézillon, Stéphane, Tyldesley, Richard, Blanpain, Cédric, Detheux, Michel, Mantovani, Alberto, Sozzani, Silvano, Vassart, Gilbert, Parmentier, Marc, Communi, David·2003·The Journal of Experimental Medicine
DOI 10.1084/jem.20030382PMC PMC2194212
Open this paper in CoChat — free accountOpen PDF

Abstract

Dendritic cells (DCs) and macrophages are professional antigen-presenting cells (APCs) that play key roles in both innate and adaptive immunity. ChemR23 is an orphan G protein-coupled receptor related to chemokine receptors, which is expressed specifically in these cell types. Here we present the characterization of chemerin, a novel chemoattractant protein, which acts through ChemR23 and is abundant in a diverse set of human inflammatory fluids. Chemerin is secreted as a precursor of low biological activity, which upon proteolytic cleavage of its COOH-terminal domain, is converted into a potent and highly specific agonist of ChemR23, the chemerin receptor. Activation of chemerin receptor results in intracellular calcium release, inhibition of cAMP accumulation, and phosphorylation of p42-p44 MAP kinases, through the Gi class of heterotrimeric G proteins. Chemerin is structurally and evolutionary related to the cathelicidin precursors (antibacterial peptides), cystatins (cysteine protease inhibitors), and kininogens. Chemerin was shown to promote calcium mobilization and chemotaxis of immature DCs and macrophages in a ChemR23-dependent manner. Therefore, chemerin appears as a potent chemoattractant protein of a novel class, which requires proteolytic activation and is specific for APCs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20030382

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Purification of the natural ligand of the ChemR23 receptor from human inflammatory fluid. (A) First step HPLC fractionation (Poros column) of human ascitic fluid. The absorbance (AU) and biological activity on ChemR23 (luminescence in an aequorin-based assay, normalized to the ATP response, solid bars) are shown. (B) Third step (cation-exchange column). (C) Fourth step (C18 column). (D) Last step purification of the active compound (C18 column). The x axis is magnified to focus on the region of interest.
Figure 1. Purification of the natural ligand of the ChemR23 receptor from human inflammatory fluid. (A) First step HPLC fractionation (Poros column) of human ascitic fluid. The absorbance (AU) and biological activity on ChemR23 (luminescence in an aequorin-based assay, normalized to the ATP response, solid bars) are shown. (B) Third step (cation-exchange column). (C) Fourth step (C18 column). (D) Last step purification of the active compound (C18 column). The x axis is magnified to focus on the region of interest.CC BY-NC-SA · PubMed Central
Figure 2. Identification of chemerin as the natural ligand of ChemR23, the chemerin receptor. (A) Monoisotopic peptide mass fingerprinting of the active fraction on a Maldi Q-TOF mass spectrometer after trypsin digestion. (B) Sequences corresponding to selected major peaks of the Maldi Q-TOF mass spectrometer spectrum after trypsin digestion. Peptides 1–7 correspond to tryptic peptides derived from the Tig-2 gene product (prochemerin), whereas peptide 8 is not tryptic and corresponds to the COOH-terminal end of the purified protein. The position of the peptides within this sequence is given. The sequence of peptides in peaks 3, 5, 7, and 8 was confirmed by microsequencing. (C) Amino acid sequence alignment of human and mouse (Protein Data Bank accession no. AK002298) preprochemerin and human cathelicidin FALL39 precursor. Amino acid identities as compared with human preprochemerin are boxed. The signal peptides (predicted for mouse preprochemerin) are in bold lowercase characters and cysteines are in bold. Cleaved COOH-terminal peptides are in bold italics and underlined (predicted by analogy for mouse prochemerin). The location of introns, which interrupt the gene coding sequences between codons, are indicated by arrowheads.
Figure 2. Identification of chemerin as the natural ligand of ChemR23, the chemerin receptor. (A) Monoisotopic peptide mass fingerprinting of the active fraction on a Maldi Q-TOF mass spectrometer after trypsin digestion. (B) Sequences corresponding to selected major peaks of the Maldi Q-TOF mass spectrometer spectrum after trypsin digestion. Peptides 1–7 correspond to tryptic peptides derived from the Tig-2 gene product (prochemerin), whereas peptide 8 is not tryptic and corresponds to the COOH-terminal end of the purified protein. The position of the peptides within this sequence is given. The sequence of peptides in peaks 3, 5, 7, and 8 was confirmed by microsequencing. (C) Amino acid sequence alignment of human and mouse (Protein Data Bank accession no. AK002298) preprochemerin and human cathelicidin FALL39 precursor. Amino acid identities as compared with human preprochemerin are boxed. The signal peptides (predicted for mouse preprochemerin) are in bold lowercase characters and cysteines are in bold. Cleaved COOH-terminal peptides are in bold italics and underlined (predicted by analogy for mouse prochemerin). The location of introns, which interrupt the gene coding sequences between codons, are indicated by arrowheads.CC BY-NC-SA · PubMed Central
Figure 3. Pharmacology of the chemerin receptor. (A) SDS/PAGE of human recombinant chemerin expressed in CHO-K1 cells and purified by HPLC. The gel was silver stained and the major band corresponds to a protein of 18 kD. Mass spectrometry analysis demonstrated the cleavage of the six COOH-terminal amino acids in this biologically active protein. (B) Biological activity on chemerinR of human recombinant chemerin (•) and prochemerin (○), using the aequorin assay. (C) Competition binding assay using as tracer an iodinated peptide derived from the chemerin COOH terminus. Competition was performed with the unlabeled peptide (□) or human recombinant chemerin (•). (D) Concentration-action curve of human chemerin in a GTPγ[35S] binding assay, using membranes of CHO/chemerinR cells. (E) Immunodetection of phosphorylated ERK1/2 in CHO/chemerinR cells after stimulation by human recombinant chemerin for 2 min. (F) Kinetics of ERK1/ ERK2 activation after stimulation by 10 nM human chemerin. Each experiment was repeated at least three times.
Figure 3. Pharmacology of the chemerin receptor. (A) SDS/PAGE of human recombinant chemerin expressed in CHO-K1 cells and purified by HPLC. The gel was silver stained and the major band corresponds to a protein of 18 kD. Mass spectrometry analysis demonstrated the cleavage of the six COOH-terminal amino acids in this biologically active protein. (B) Biological activity on chemerinR of human recombinant chemerin (•) and prochemerin (○), using the aequorin assay. (C) Competition binding assay using as tracer an iodinated peptide derived from the chemerin COOH terminus. Competition was performed with the unlabeled peptide (□) or human recombinant chemerin (•). (D) Concentration-action curve of human chemerin in a GTPγ[35S] binding assay, using membranes of CHO/chemerinR cells. (E) Immunodetection of phosphorylated ERK1/2 in CHO/chemerinR cells after stimulation by human recombinant chemerin for 2 min. (F) Kinetics of ERK1/ ERK2 activation after stimulation by 10 nM human chemerin. Each experiment was repeated at least three times.CC BY-NC-SA · PubMed Central
Figure 4. Expression of human chemerin and its receptor. (A) Conversion of 100 nM human recombinant prochemerin in conditioned medium from hamster CHO-K1 cells. Conversion rate was estimated by comparing the biological activity with that of the same molar amount of purified processed chemerin. (B and C) Transcripts encoding human chemerinR (B) and prochemerin (C) were amplified by quantitative RT-PCR in a set of human tissues and cell populations. PBMC, peripheral blood mononuclear cells; iDC, immature DCs. (D and E) The expression of chemerinR was analyzed by FACS® in immature (solid line) and mature DCs (gray area) after stimulation by LPS (D) or CD40L (E), using the 1H2 monoclonal antibody (IgG2A). Control labeling (dotted line) was made with an antibody of the same isotype. (F) ChemerinR expression on macrophages was monitored using the 1H2 (thick solid line) and 4C7 (thin solid line) monoclonal antibodies. Control labeling (dotted line) was made with an antibody of the same isotype.
Figure 4. Expression of human chemerin and its receptor. (A) Conversion of 100 nM human recombinant prochemerin in conditioned medium from hamster CHO-K1 cells. Conversion rate was estimated by comparing the biological activity with that of the same molar amount of purified processed chemerin. (B and C) Transcripts encoding human chemerinR (B) and prochemerin (C) were amplified by quantitative RT-PCR in a set of human tissues and cell populations. PBMC, peripheral blood mononuclear cells; iDC, immature DCs. (D and E) The expression of chemerinR was analyzed by FACS® in immature (solid line) and mature DCs (gray area) after stimulation by LPS (D) or CD40L (E), using the 1H2 monoclonal antibody (IgG2A). Control labeling (dotted line) was made with an antibody of the same isotype. (F) ChemerinR expression on macrophages was monitored using the 1H2 (thick solid line) and 4C7 (thin solid line) monoclonal antibodies. Control labeling (dotted line) was made with an antibody of the same isotype.CC BY-NC-SA · PubMed Central
Figure 5. Biological activity of chemerin on primary cells. (A) Inhibition of the functional response of CHO-K1 cells expressing the chemerinR (aequorin assay) by the 4C7 anti-chemerinR monoclonal antibody. The cells were preincubated for 30 min at room temperature with various amounts of the 4C7 antibody before stimulation by 10 nM recombinant chemerin. The data were normalized according to the response in the absence of antibody (100%) and in the absence of agonist (0%). (B) Chemotaxis of human immature DCs by recombinant chemerin. Results are expressed as the mean ± SD (n = 3) and are representative of three donors. (C) 10 pM chemerin-induced DC migration was inhibited by 3 μg/ml pertussis toxin pretreatment of the cells, as well as by preincubation of the cells with 10 μg/ml of the 4C7 monoclonal antibody. Checkerboard analysis investigates chemotactic versus chemokinetic effects of chemerin on DCs. 10 pM human chemerin was added to the lower and/or upper chamber of the chemotaxis device. 10 nM of the chemokine RANTES was used as a positive control in the experiments. (D) Ca2+ flux in monocyte-derived DCs in response to 30 nM recombinant chemerin (arrow). (E) The same experiment after 30 min preincubation of the cells with 10 μg/ml of the 4C7 monoclonal antibody. (F) Chemerin-induced macrophage migration (10 and 100 pM) and its inhibition by 3 μg/ml pertussis toxin pretreatment and 10 μg/ml 4C7 monoclonal antibody. Checkerboard analysis investigates chemotactic versus chemokinetic effects of chemerin on macrophages. (G) Ca2+ flux in macrophages in response to 30 nM recombinant chemerin (arrow). (H) The same experiment after 30 min preincubation of the cells with 10 μg/ml of the 4C7 monoclonal antibody.
Figure 5. Biological activity of chemerin on primary cells. (A) Inhibition of the functional response of CHO-K1 cells expressing the chemerinR (aequorin assay) by the 4C7 anti-chemerinR monoclonal antibody. The cells were preincubated for 30 min at room temperature with various amounts of the 4C7 antibody before stimulation by 10 nM recombinant chemerin. The data were normalized according to the response in the absence of antibody (100%) and in the absence of agonist (0%). (B) Chemotaxis of human immature DCs by recombinant chemerin. Results are expressed as the mean ± SD (n = 3) and are representative of three donors. (C) 10 pM chemerin-induced DC migration was inhibited by 3 μg/ml pertussis toxin pretreatment of the cells, as well as by preincubation of the cells with 10 μg/ml of the 4C7 monoclonal antibody. Checkerboard analysis investigates chemotactic versus chemokinetic effects of chemerin on DCs. 10 pM human chemerin was added to the lower and/or upper chamber of the chemotaxis device. 10 nM of the chemokine RANTES was used as a positive control in the experiments. (D) Ca2+ flux in monocyte-derived DCs in response to 30 nM recombinant chemerin (arrow). (E) The same experiment after 30 min preincubation of the cells with 10 μg/ml of the 4C7 monoclonal antibody. (F) Chemerin-induced macrophage migration (10 and 100 pM) and its inhibition by 3 μg/ml pertussis toxin pretreatment and 10 μg/ml 4C7 monoclonal antibody. Checkerboard analysis investigates chemotactic versus chemokinetic effects of chemerin on macrophages. (G) Ca2+ flux in macrophages in response to 30 nM recombinant chemerin (arrow). (H) The same experiment after 30 min preincubation of the cells with 10 μg/ml of the 4C7 monoclonal antibody.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Research works printed but not linked: 3

  1. 2000, Clin. Exp. Immunol., 119, 486
  2. 2000, Pharmacol. Rev., 52, 145
  3. 2002, Genome Biol., 3, 0063

Cited by

Sorted by citations

See all 891

Related

Metadata

Authors
Wittamer, V., Franssen, J.-D., Vulcano, M., Mirjolet, J.-F., Le Poul, E., Migeotte, I., Brézillon, S., Tyldesley, R., Blanpain, C., Detheux, M., Mantovani, A., Sozzani, S., Vassart, G., Parmentier, M., & Communi, D.
Affiliations
  • 1Institut de Recherche en Biologie Humaine et Moléculaire, B-1070 Brussels, Belgium
  • Euroscreen (Belgium) (BE)
  • Mario Negri Institute for Pharmacological Research (IT)
  • 2Euroscreen s.a., B-6041 Gosselies, Belgium
  • 4Micromass Ltd., Manchester M23 9LZ, United Kingdom
  • University of Milan (IT)
Corresponding author
Parmentier, Marc
ORCID
Venue
The Journal of Experimental Medicine
Publisher
Rockefeller University Press
Published
2003-10-06
Volume
198
Issue
7
Pages
977-985
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
DOI
10.1084/jem.20030382
PMC
PMC2194212
OpenAlex
W2168015220
Cited by
888
References
31
Citations by year
2026: 22 · 2025: 33 · 2024: 38 · 2023: 40 · 2022: 50 · 2021: 42 · 2020: 65 · 2019: 43 · 2018: 57 · 2017: 44 · 2016: 55 · 2015: 55 · 2014: 63 · 2013: 53 · 2012: 51
FWCI
4.79
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
  • Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
Funders
  • Waalse Gewest
  • Fédération Wallonie-Bruxelles
  • Associazione Italiana per la Ricerca sul Cancro
  • Fondation Médicale Reine Elisabeth
Topics
  • Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
  • Life Sciences › Immunology and Microbiology › Microbiology › Antimicrobial Peptides and Activities
Keywords
chemerin, ChemR23, G protein-coupled receptors, dendritic cells, macrophages, antigen-presenting cells, chemoattractants, proteolytic processing, intracellular calcium release, cAMP inhibition, MAPK phosphorylation, chemotaxis, kininogen, cystatin
MeSH terms
Amino Acid Sequence, Antigen-Presenting Cells, Calcium, Cell Movement, Dendritic Cells, Humans, Molecular Sequence Data, Chemokines, Receptors, Chemokine, Intercellular Signaling Peptides and Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review